PPMD Recommends Marathon Convene Broad Array of Duchenne Stakeholders to Discuss Re-evaluation of Deflazacort Pricing
In light of the pause in commercialization of EMFLAZA ™ (deflazacort) by Marathon Pharmaceuticals earlier this week, PPMD recommends that Marathon seek input from a broad array of stakeholders including Duchenne clinicians, health insurance plans, pharmacy benefit managers, and Duchenne advocacy groups.
Source: Parent Project Muscular Dystrophy - Category: Neurology Source Type: news
More News: Health Insurance | Insurance | Muscular Dystrophy | Neurology | Reflex Sympathetic Dystrophy